FDA approves multiple sclerosis drug from Biogen and Alkermes
Oct 30 (Reuters) - Biogen Inc BIIB.O and partner Alkermes Plc ALKS.O said on Wednesday that the U.S. Food and Drug Administration approved their oral drug to treat multiple sclerosis.
The drug, Vumerity, was approved to treat relapsing forms of multiple sclerosis, a disabling autoimmune disease that damages the central nervous system and can lead to fatigue, pain, vision loss and impaired coordination and motor skills.
Biogen, which also sells multiple sclerosis treatment Tecfidera, said it would make the drug available in the United States in the near future.
Earlier this month, Alkermes disclosed that the drug had received tentative approval.
(Reporting by Tamara Mathias in Bengaluru Editing by Supriya Kurane)
((Tamara.Mathias@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 1208;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Latest Markets Videos
- US STOCKS-Wall St plunges as Snap's bleak forecast sparks selloff
- US STOCKS-Wall Street surges on upbeat retail guidance, easing Fed fears
- All Fed officials backed May rate hike, 'most' saw half-point rises in June and July, minutes show
- Fed could cut rates in 2023, 2024 once inflation under control -Bullard